“Spain is a pioneer country in the development of biotechnology startups and companies like Neuro-Bio”

Neuro-Bio is a biotechnology company from the UK that develops treatments for Alzheimer’s disease (AD). The company is now looking to attract up to £10 million  in stages to advance in the clinical development of its new molecule, NBP 14

Thanks to their project, Susan Greenfield, CEO and founder, and Sara García Rates, Operations Director and member of Neuro-Bio since it was founded in 2013, are now part of Rising UP in Spain at ICEX-Invest in Spain. In fact, the programme is focused on capturing foreign entrepreneurs that want to become established and grow in Spain. The selected startups receive resources to develop their business in Spain.

Some of the financial support you have received has come from Rising Up Spain. What does this recognition and support mean for you?
From the point of view of recognition, it is an honour: Being selected for this programme has shown that Neuro-Bio is an attractive company, with good ideas and good management organisation. And there is the support the programme has opened up to us to in the Spanish and European markets, with enormous possibilities for collaboration with companies and research centres headquartered in Spain who did not know us before we were selected. 

Why do you want to come to Spain? What is this process like?
Neuro-Bio is a growing company that has been involved with various collaborations and joint projects with Spanish companies since the start. These projects and collaborations in Spain have shown that it is a good location in which to develop them. What is more, Spain is a pioneer country for biotechnology startups and companies like Neuro-Bio.

How important is it that public institutions support projects of this type? What are your needs in this respect?
In the case of Neuro-Bio and companies like ours, involved in the development of drugs for AD or cancer, it is indispensable  for public institutions to finance projects of this type. The public health service spends millions of euros helping people that suffer from these illnesses and they would benefit from treatments.

What are you expecting from this country and what can it expect from you? 
The successful development of a biomarker and a treatment for AD, and possibly one for metastasis in cancer, via collaborations, projects, financing, etc. We hope to find a potential partner to meet these challenges so that our treatments can reach the patient.

Source: El Referente
Read the full interview: https://elreferente.es/entrevistas/neuro-bio-tratamiento-alzheimer/

Photo: Neuro-Bio